Opus Genetics surges on gene therapy breakthrough, $70M cash runway
Clinical-stage biotech reports positive data for retinal disease treatments, advances Phase 3 programs
Opus Genetics shares have surged more than 160 percent over the past year, driven by breakthrough clinical trial data for its gene therapies targeting inherited retinal diseases and a strengthened balance sheet that funds operations into 2028. The clinical-stage biotechnology company reported annual revenue of $14.2 million for full year 2025, a 29 percent increase from $11.0 million in the prior year, according to regulatory filings.
The revenue growth, derived primarily from license and collaboration agreements with Viatris, helped bolster the company's cash position to $70.1 million pro forma as of March 2026. This figure includes approximately $25 million raised through a private placement in February, providing operating runway into the first half of 2028.
The stock's dramatic ascent comes as investors respond to promising clinical data from the company's lead programs. On February 27, Opus Genetics announced initial Phase 1/2 results for OPGx-BEST1, a gene therapy targeting BEST1-related retinal diseases. The first adult participant demonstrated a 12-letter gain in Best Corrected Visual Acuity and a 23 percent reduction in central subfield thickness, with no ocular inflammation or treatment-related adverse events reported at three months.
"The early signals of functional and structural improvement observed in the first participant are highly encouraging for patients living with BEST1-related inherited retinal diseases," the company stated in its press release. Full cohort data from the OPGx-BEST1 study is expected in mid-2026.
Simultaneously, the company is advancing its OPGx-LCA5 program toward a pivotal Phase 3 trial in the second half of 2026. The gene therapy targets Leber congenital amaurosis type 5, a severe form of inherited retinal degeneration that causes blindness in childhood. Previous Phase 1/2 data showed durable vision improvements in both adult and pediatric patients.
The clinical progress has attracted strong analyst support, with price targets ranging from $7.00 to $12.00 as of March 2026. The consensus target of $8.00 represents significant upside from the current trading level around $4.77, reflecting confidence in the company's pipeline execution. Twelve analysts cover the stock, with 11 maintaining buy ratings and one strong buy, according to market data.
Opus Genetics, which trades on NASDAQ under ticker IRD, has established a market capitalization of approximately $337 million. The company's focus on rare retinal diseases represents a strategic bet on gene therapy platforms that could address critical unmet medical needs while delivering substantial commercial potential if therapies reach approval.
Beyond its core pipeline, Opus Genetics also announced in February that the FDA accepted its supplemental New Drug Application for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia, with a regulatory decision expected by October 17, 2026. This represents a potential near-term revenue opportunity alongside its gene therapy development efforts.
The company's ability to simultaneously advance multiple clinical programs while securing extended financial runway has positioned it as a notable player in the gene therapy space. With multiple data readouts anticipated in 2026 and Phase 3 initiation for OPGx-LCA5 expected in the second half of the year, investors will be closely monitoring the company's progress toward bringing sight-restoring therapies to patients with inherited retinal diseases.